Telisotuzumab vedotin
As of the edition of 20 October 2026, Telisotuzumab vedotin is an antibody drug conjugate: marketed, first approved in 2025 (US); acts on MET, TUBB and TUBB1 and 7 more; US protection ends in 2037.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Antibody drug conjugate
- Brand name
- Emrelis
- First approved
- 14 May 2025 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- AbbVie
- Registered trials
- 10, 2 stopped early
- Disease areas
- Cancer; Lungs and airways
US protection
US protection ends in 2037.
US protection ends in 2037, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by AbbVie. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
Companies that need a new molecule because of this drug
10 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product10 company-target rows are on route B because of Telisotuzumab vedotin.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| TUBB4A | Tubulin beta-4A chain | P04350 |
| TUBB | Tubulin beta chain | P07437 |
| MET | Hepatocyte growth factor receptor | P08581 |
| TUBB4B | Tubulin beta-4B chain | P68371 |
| TUBB3 | Tubulin beta-3 chain | Q13509 |
| TUBB2A | Tubulin beta-2A chain | Q13885 |
| TUBB8 | Tubulin beta-8 chain | Q3ZCM7 |
| TUBB6 | Tubulin beta-6 chain | Q9BUF5 |
| TUBB2B | Tubulin beta-2B chain | Q9BVA1 |
| TUBB1 | Tubulin beta-1 chain | Q9H4B7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 2 | 1 | 1 | 0 |
| Phase 2 | 5 | 1 | 3 | 1 |
| Phase 3 | 2 | 0 | 1 | 1 |
| All trials | 10 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Originator and Lead sponsor of trials | 2022 to now |